- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02525315
Interest of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Auditory Hallucinations (TMS HALLU)
Auditory hallucinations are common (present in 60-70% of cases) and extremely debilitating. Behavioral disorders associated with them can have serious social repercussions. However, in 25% of cases the usual antipsychotic drug treatments are incompletely or totally ineffective.
Fifteen subjects will be included after collection and signed their informed consent.
The rTMS treatment is made of 4 sessions of 13 minutes spread over two days, at a frequency of 20 Hz and an intensity of 80% of motor threshold at rest. These constants are used to stay below the risk of occurrence of seizures, the only serious side effects identified. Furthermore the rTMS treatment is almost painless: tension headaches are the main side effects and make amends with simple analgesics. rTMS is devoid of neurocognitive effects. The LEFT stimulation site will be established through a anatomofunctional imaging before treatment (between D-7 and D0).
Treatment efficacy will be evaluated daily during treatment (days 1 and 2) and during the first 2 weeks of starting treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Caen, France, 14033
- Caen University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with schizophrenic disorders aged from 18 to 60 years old
- Patients suffering from auditory hallucinations undergoing antipsychotic treatments
- Written signed consent
Exclusion Criteria:
- Pregnancy or breastfeeding
- Counter-indication to MRI or to rTMS
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Transcranial magnetic stimulation: rTMS
rTMS : 4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
|
4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
HOFFMAN score
Time Frame: change between baseline and day 3 or day 12
|
change between baseline and day 3 or day 12
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sonia Dollfus, MD, PhD, University Hospital, Caen
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 06-137
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenic Disorders
-
AstraZenecaCompletedSchizophrenic DisorderBulgaria, Russian Federation, Romania, South Africa, Greece, Philippines, India, Indonesia
-
Shanghai Mental Health CenterStanley Medical Research InstituteWithdrawnCognitive Impairment | Schizophrenic DisorderChina
-
Shalvata Mental Health CenterBar-Ilan University, IsraelUnknownSchizophrenic PatientsIsrael
-
University of WashingtonRecruitingSchizophrenic Spectrum DisorderGhana
-
Tanta UniversityCompleted
-
JanuelUnknownThe Impact of Stigma on the Quality of Life of People With Schizophrenic Disorders and Their Siblings
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Northeast Normal UniversityCompletedSchizophrenic PatientsChina
-
Northeast Normal UniversityCompletedSchizophrenic PatientsChina
-
US Department of Veterans AffairsCompletedSchizophrenia | Schizophrenic DisorderUnited States
Clinical Trials on Transcranial magnetic stimulation: rTMS
-
Centre Hospitalier Universitaire de NiceCompletedPost-traumatic Stress DisorderFrance
-
MGH Institute of Health ProfessionsNational Institute on Deafness and Other Communication Disorders (NIDCD)Recruiting
-
Krystal Parker, PhDRecruitingDepression | Schizophrenia | Parkinson Disease | Bipolar Disorder | Autism Spectrum DisorderUnited States
-
University of California, San DiegoNational Institute of Mental Health (NIMH)RecruitingMajor Depressive Disorder | Treatment Resistant DepressionUnited States, Australia
-
Masaryk UniversityCompletedParkinson DiseaseCzechia
-
Brigham and Women's HospitalBeth Israel Deaconess Medical Center; Mclean HospitalRecruitingObesity | Appetitive BehaviorUnited States
-
Mclean HospitalNational Institute of Mental Health (NIMH); Beth Israel Deaconess Medical CenterRecruitingSchizophrenia | Schizo Affective DisorderUnited States
-
Kaohsiung Veterans General Hospital.RecruitingBipolar II Disorder, Most Recent Episode Major DepressiveTaiwan
-
Yi YangNot yet recruiting
-
Tehran University of Medical SciencesUnknownBorderline Personality Disorder